The efficacy and toxicity of neoadjuvant carboplatin and paclitaxel administered on a weekly schedule for locally advanced cervical carcinoma were evaluated. Thirty patients staged as IB2–IVA according to the FIGO were treated with carboplatin (AUC 2; an area under the time-concentration of 2 mg*min/ml based on creatinine clearance) and paclitaxel (60 mg/m2) intravenously, every week for six cycles. A type III radical hysterectomy was then undertaken. Thirty patients were enrolled in this study. An objective response was recorded in 26 patients (87%, 95% CI 70–95%). Progressive disease was not observed. Grade 3 neutropenia was observed in only two patients (7%), and grade 1 or 2 neuropathy was seen in six patients (20%). The combination of carboplatin and paclitaxel given in weekly schedule for advanced cervical carcinoma was highly active, permitting a high rate of subsequent surgical resectability. It was well tolerated. This regimen may provide improved outcomes with minimal toxicity.
- cervical cancer
- neoadjuvant chemotherapy
- weekly schedule
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.